Sanofi(US:SNY) Zhong Guo Xin Wen Wang·2025-11-04 09:35Core Viewpoint - Sanofi views the China International Import Expo (CIIE) as a vital platform for connecting China with the global market, facilitating the rapid introduction of innovative healthcare solutions and deepening integration into the local healthcare ecosystem [1][5]. Group 1: Participation in CIIE - Sanofi has participated in the CIIE for eight consecutive years, leveraging the event's "spillover effect" to accelerate the introduction of innovative drugs into China [2][6]. - The company will showcase 10 innovative products at this year's expo, focusing on key health issues such as cardiovascular diseases, metabolic disorders, respiratory diseases, tumors, and rare diseases [2][5]. Group 2: Innovation and Market Strategy - Sanofi's strategy includes using the CIIE as a launchpad for global product debuts, which allows the company to convert its "first-mover advantage" into market benefits, ensuring that innovative drugs reach Chinese patients quickly [5][6]. - The company has introduced over 60 innovative drugs and vaccines in China, addressing seven of the top ten causes of death in the country and providing immunization for over 10 million people annually [5][6]. Group 3: Local Manufacturing and Investment - Sanofi is investing €1 billion to establish a new insulin raw material production facility in Beijing, marking a significant commitment to local manufacturing as it approaches 30 years of operations in China [7][8]. - The new facility will enhance Sanofi's supply chain resilience and support the company's transition from "Made in China" to "Intelligently Made in China" [8][9]. Group 4: Long-term Vision and Collaboration - Sanofi aims to become a leading multinational pharmaceutical company in China by 2030, focusing on long-term partnerships with local enterprises to explore comprehensive innovation collaborations [9]. - The company has established three production bases and four R&D centers in China, creating an end-to-end value chain from research and development to commercial operations [8][9].